May 15, 2018
Two malaria experts in the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine wrote a commentary published in the June Issue of The Lancet Global Health discussing the prevalence of malaria in school-age children in sub-Saharan Africa. Miriam Laufer, MD, Associate Professor of Pediatrics and Associate Director for Malaria Research CVD, and Lauren Cohee, MD, Instructor, Pediatrics, noted that often malaria infection is more common in school-age children than younger children and adults.
“After almost two decades of substantial reductions in the global burden of malaria, progress has stagnated. Global scientific and policy leaders agree that to achieve malaria eradication, interventions must focus not only on preventing malaria disease but also on decreasing malaria transmission. Children younger than 5 years and pregnant women are at the highest risk of severe disease and have previously been the primary targets of malaria control interventions. However, apparently healthy older children and adults also harbor transmissible malaria parasites,” Drs. Laufer and Cohee wrote.
Listen to the Podcast >>
About the Center for Vaccine Development and Global Health
For over 40 years, researchers in the Center for Vaccine Development and Global Health have worked domestically and internationally to develop, test, and deploy vaccines to aid the world’s underserved populations. The CVD is an academic enterprise engaged in the full range of infectious disease intervention from basic laboratory research through vaccine development, pre-clinical and clinical evaluation, large-scale pre-licensure field studies, and post-licensure assessments. CVD has worked to eliminate vaccine-preventable diseases. The CVD has created and tested vaccines against cholera, typhoid fever, paratyphoid fever, non-typhoidal salmonella disease, shigellosis (bacillary dysentery), Escherichia coli diarrhea, nosocomial pathogens, tularemia, influenza, and other infectious diseases.
CVD’s research covers the broader goal of improving global health by conducting innovative, leading research in Baltimore and around the world. CVD researchers are developing new and improved ways to diagnose, prevent, treat, control, and eradicate diseases of global impact. Currently, these diseases include malaria, typhoid, shigella and vaccine-preventable infectious diseases. CVD researchers have been involved in critical vaccine development for emerging pathogens such as Zika and Ebola. In addition, CVD’s work focuses on the ever-growing challenge of anti-microbial resistance. medschool.umaryland.edu/CVD/
Contact
Department of Anesthesiology
(410) 328-6120 (phone)
(410) 328-5531 (fax)
newsletter@som.umaryland.edu
Center for Vaccine Development and Global Health
University of Maryland School of Medicine
jmorrison@som.umaryland.edu
Office:(410) 706-2884
Related stories
Thursday, March 28, 2024
NIH selects Dr. Kathleen Neuzil as Director of The Fogarty International Center
Kathleen M. Neuzil, MD, MPH, Director of the University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health, has been named the 13th director of the Fogarty International Center (FIC), which is part of the National Institutes of Health (NIH). Dr. Neuzil will be the first woman to hold the permanent directorship since the center’s founding in 1968 and will also hold the position of Associate Director for International Research at NIH.
Tuesday, December 20, 2022
COVID Vaccines Prevented 3 Million Deaths in the U.S., New Analysis Finds
In the two years since the first COVID-19 vaccines were given to patients in the U.S., the vaccines had the cumulative effect of preventing 18 million hospitalizations and 3 million deaths. That is based on a new modeling analysis conducted by a researcher at the University of Maryland School of Medicine (UMSOM) and her colleagues. Results of the analysis were published by the Commonwealth Fund.
Friday, February 05, 2021
UM School of Medicine Researchers Demonstrate Strong Immune Response for New COVID-19 Vaccine in Pre-Clinical Tests
Researchers at the University of Maryland School of Medicine (UMSOM) have found promising results in pre-clinical studies for a new experimental vaccine against COVID-19 made by Novavax. The vaccine was found to generate a robust immune response in animals exposed to the vaccine with strong data indicating safety and efficacy, according to the study published recently in the journal Nature Communications. The results have been used to begin testing the vaccine in human trials in the U.S. with a Phase 3 trial that recently launched at the UMSOM’s Center for Vaccine Development and Global Health.
Wednesday, August 05, 2020
UMSOM Acclaimed Physician-Scientist and Student Mentor, Dr. Miriam Laufer, to Join Academic Affairs Leadership Team as Assistant Dean for Medical Student Research Education
University of Maryland School of Medicine (UMSOM) Vice Dean for Academic Affairs, James Kaper, PhD, along with UMSOM Dean E. Albert Reece, MD, PhD, MBA, announced that Miriam Laufer, MD, MPH, Professor of Pediatrics and Associate Director of the Center for Vaccine Development and Global Health (CVD), will join the Academic Affairs leadership team as Assistant Dean for Medical Student Research Education.
Tuesday, December 10, 2019
UMSOM Researchers to Test Vaccine Designed to Protect Against Serious Illness from Contaminated Food and Water
Each year, millions of people contract serious diarrheal illnesses typically from contaminated food and water. Among the biggest causes of diarrheal diseases are the bacteria Shigella and enterotoxigenic Escherichia coli (ETEC), and researchers at the University of Maryland School of Medicine are testing a vaccine designed to offer protection against these serious pathogens.
Friday, September 20, 2019
UM School of Medicine's Center for Vaccine Development and Global Health Receives NIH Contract of up to More than $200 Million for Influenza Research
Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) and Dean E. Albert Reece, MD, PhD, MBA, announced that CVD has been awarded a contract from the National Institute of Allergy and Infectious Diseases (NIAID), with total funding up to more than $200 million over seven years if all contract options are exercised.
Monday, August 19, 2019
UM School of Medicine Researcher Warns of Need for Malaria Drug to Treat Severe Cases in U.S.
Each year there are more than 200 million cases of malaria worldwide, a mosquito-borne disease caused by a parasite that brings on fever and body aches and, in some cases, more serious conditions such as coma and death. While the vast majority of these cases occur in sub-Saharan Africa and South Asia, the U.S. each year sees more than 1,500 cases, and currently there is limited access to an intravenously-administered (IV) drug needed for the more serious cases, according to a top malaria researcher at the University of Maryland School Medicine (UMSOM).
Tuesday, August 13, 2019
UM School of Medicine Researchers Begin Phase 1 Clinical Trial of Vaccine Against Mosquito-Borne Diseases
Mosquito-borne diseases including malaria, dengue and yellow fever, have a severe impact resulting in millions of deaths worldwide, hitting the world’s most vulnerable populations the hardest. Researchers at the University of Maryland School of Medicine (UMSOM) have begun testing an experimental vaccine that is designed to protect against a series of these diseases.
Friday, November 02, 2018
UMSOM Global Health Expert Named to Prestigious World Health Organization Immunization Panel
Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), has been named to the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization.
Sunday, October 28, 2018
American Society of Tropical Medicine & Hygiene Awards Dr. Miriam Laufer the LePrince Medal for Malaria Research
Miriam Laufer, MD, MPH, Professor of Pediatrics and Associate Director for Malaria Research at the University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health (CVD), was awarded the Joseph Augustin LePrince Medal by the American Society of Tropical Medicine and Hygiene (ASTMH).
Wednesday, June 06, 2018
UMSOM Researchers Find that Silent Carriers of Malaria are Unlikely to Develop the Disease
In regions where malaria illness is widespread, it is common to find many individuals who are infected with malaria parasites (Plasmodium falciparum), but without symptoms. New research conducted by the University of Maryland School of Medicine (UMSOM) shows that treating these silent malaria cases could help stop the spread of malaria to others.